OncoMatch/Clinical Trials/NCT05920356
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Is NCT05920356 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Sotorasib and Pembrolizumab for non-small cell lung cancer (nsclc).
Treatment: Sotorasib · Pembrolizumab — The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants who receive pembrolizumab with platinum doublet chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: KRAS G12C
KRAS p. G12C mutation
Required: PD-L1 (CD274) negative for expression (negative)
negative for PD-L1 expression by central testing or local laboratory testing confirmed through central testing
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: KRAS G12C inhibitor
Prior therapy with a KRAS G12C inhibitor
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sansum Clinic · Santa Barbara, California
- Medical Oncology Hematology Consultants Helen F Graham Cancer Center · Newark, Delaware
- University of Illinois Chicago · Chicago, Illinois
- Illinois Cancer Specialists · Niles, Illinois
- Norton Cancer Institute - Brownsboro · Louisville, Kentucky
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05920356 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require KRAS?
Yes, KRAS G12C is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 negative for expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify